PURPOSE: To evaluate the incidence of venous thromboembolism (VTE) in ambulatory pancreas cancer patients receiving chemotherapy and analyze Khorana's predictive model of chemotherapy-associated thrombosis. METHODS/PATIENTS: We performed a retrospective review to determine the incidence of VTE in the gastrointestinal cancer unit of our center. Between 2008 and 2011, 84 consecutives patients diagnosed with pancreas adenocarcinoma were identified and included in the analysis. Pancreatic neuroendocrine tumors were excluded. RESULTS: Thirty patients experienced VTE (35.7 %) and 66 % of the events were diagnosed during the first 6 months after diagnosis. Khorana's score: 33.3 % of the intermediate category patients developed a venous thromboembolic event and 37.5 % in the high-risk category. CONCLUSIONS: The high incidence of VTE observed in this study is consistent with prior reports. Specific predictive model for chemotherapy-associated thrombosis in pancreatic cancer must be investigated.
PURPOSE: To evaluate the incidence of venous thromboembolism (VTE) in ambulatory pancreas cancerpatients receiving chemotherapy and analyze Khorana's predictive model of chemotherapy-associated thrombosis. METHODS/PATIENTS: We performed a retrospective review to determine the incidence of VTE in the gastrointestinal cancer unit of our center. Between 2008 and 2011, 84 consecutives patients diagnosed with pancreas adenocarcinoma were identified and included in the analysis. Pancreatic neuroendocrine tumors were excluded. RESULTS: Thirty patients experienced VTE (35.7 %) and 66 % of the events were diagnosed during the first 6 months after diagnosis. Khorana's score: 33.3 % of the intermediate category patients developed a venous thromboembolic event and 37.5 % in the high-risk category. CONCLUSIONS: The high incidence of VTE observed in this study is consistent with prior reports. Specific predictive model for chemotherapy-associated thrombosis in pancreatic cancer must be investigated.
Authors: Andrew S Epstein; Gerald A Soff; Marinela Capanu; Christopher Crosbie; Manish A Shah; David P Kelsen; Brian Denton; Stuart Gardos; Eileen M O'Reilly Journal: Cancer Date: 2011-10-11 Impact factor: 6.860
Authors: A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas Journal: Eur J Cancer Date: 2011-11-17 Impact factor: 9.162
Authors: Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie Journal: N Engl J Med Date: 2012-02-16 Impact factor: 91.245
Authors: B Laquente; A Calsina-Berna; A Carmona-Bayonas; P Jiménez-Fonseca; I Peiró; A Carrato Journal: Clin Transl Oncol Date: 2017-06-13 Impact factor: 3.405
Authors: A J Muñoz Martín; E Gallardo Díaz; I García Escobar; R Macías Montero; V Martínez-Marín; V Pachón Olmos; P Pérez Segura; T Quintanar Verdúguez; M Salgado Fernández Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: B A Boone; L Orlichenko; N E Schapiro; P Loughran; G C Gianfrate; J T Ellis; A D Singhi; R Kang; D Tang; M T Lotze; H J Zeh Journal: Cancer Gene Ther Date: 2015-04-24 Impact factor: 5.987
Authors: Nick van Es; Marcello Di Nisio; Gabriela Cesarman; Ankie Kleinjan; Hans-Martin Otten; Isabelle Mahé; Ineke T Wilts; Desirée C Twint; Ettore Porreca; Oscar Arrieta; Alain Stépanian; Kirsten Smit; Michele De Tursi; Suzanne M Bleker; Patrick M Bossuyt; Rienk Nieuwland; Pieter W Kamphuisen; Harry R Büller Journal: Haematologica Date: 2017-05-26 Impact factor: 9.941
Authors: Jong-Chan Lee; Young Sun Ro; Junhyeon Cho; Yohan Park; Ji Hye Lee; Jin-Hyeok Hwang; Hye Jin Choi; Soohyeon Lee Journal: Medicine (Baltimore) Date: 2016-04 Impact factor: 1.889
Authors: Andrés J Muñoz Martín; Israel Ortega; Carme Font; Vanesa Pachón; Victoria Castellón; Virginia Martínez-Marín; Mercedes Salgado; Eva Martínez; Julia Calzas; Ana Rupérez; Juan C Souto; Miguel Martín; Eduardo Salas; Jose M Soria Journal: Br J Cancer Date: 2018-03-28 Impact factor: 7.640